lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· May 28, 2026

Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD

View original at globenewswire.com
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ZB021 is a novel, potentially best-in-class, oral small molecule IL-17AA/AF inhibitor

    60% confidence
  • Obexelimab has been evaluated in eight clinical trials in a total of 383 subjects, including INDIGO, and was well tolerated with demonstrated clinical activity across all trials

    60% confidence
  • The INDIGO open label extension will further build upon the largest body of clinical data reported for IgG4-RD patients to date

    60% confidence
  • ZB022 is a preclinical, potentially best-in-class, oral, brain-penetrant, TYK2 inhibitor

    60% confidence
  • Obexelimab met and demonstrated highly statistically significant activity compared to placebo on all four key secondary endpoints in INDIGO and was generally well tolerated

    60% confidence
  • Obexelimab demonstrated a highly statistically significant and clinically meaningful 56% reduction in the risk of IgG4-RD flare compared to placebo (Hazard Ratio 0.44, p=0.0005) during the 52-week randomized placebo-controlled period of INDIGO

    60% confidence
  • Zenas expects to report topline SLE Phase 2 trial results, including biomarker data, in the fourth quarter of 2026

    60% confidence
  • Orelabrutinib is a potentially best-in-class, highly selective CNS-penetrant, oral, small molecule BTK inhibitor that targets pathogenic B cells in both the periphery and CNS, and directly modulates macrophages and microglial cells, with potential to address compartmentalized inflammation and disease progression in MS

    60% confidence
  • The BLA submission brings Zenas one step closer to delivering a meaningful treatment option to patients living with IgG4-RD; based on INDIGO clinical activity and safety profile, obexelimab may have an important role as a first-line therapy in long-term management of IgG4-RD

    60% confidence
Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD: Source | Via News | fr.via.news